Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2013

View Archived Issues

Ono Pharmaceutical reports highlights of second quarter of fiscal 2013

Lundbeck reflects on active third quarter 2013

Nuvilex acquires rights to cellulose-based live-cell encapsulation technology for diabetes

Anti-LOXL2 antibody suppresses collagen cross-linking and fibrosis progression in vivo

Advanced Proteome Therapeutics achieves milestone in cancer program

University of Virginia to study PTP-01 as imaging agent for pancreatic cancer

Phase II clinical data demonstrate efficacy for an antibody to treat adipocytic sarcoma

ACEA Biosciences' AC-0025 shows antiarthritic activity in vivo

Novel tyrosine-protein kinase inhibitors patented by Advinus Therapeutics

Dainippon Sumitomo Pharma prepares new 11-beta-HSD1 inhibitors

New cathepsin S inhibitors disclosed by Astellas Pharma

Biodel advances ultra-rapid-acting insulin product BIOD-531 into clinical development

New fusion proteins to reactivate apoptosis in TRAIL/Apo-2L-resistant cancer cells described

New Hsp70 inducers presented by scientists in the Netherlands

Drug repositioning detects efficacy of drugs for malaria

Immuron cleared to conduct trial of IMM-124-E for alcoholic steatohepatitis

Eisai and Broad Institute to develop new drugs for neglected tropical diseases

Discovery Laboratories begins U.S. launch of Surfaxin

CereSpir acquires rights to cognitive impairment treatment candidate

FDA clears CERC-301 for phase II study in major depression

Grifols to acquire Novartis' transfusion diagnostics unit

GW Pharmaceuticals initiates phase Ib/IIa study of cannabinoids for glioblastoma multiforme

FDA approves Aptiom as adjunctive treatment for partial-onset seizures

Eisai launches Aciphex Sprinkle in U.S.

Shire to acquire ViroPharma

Salix Pharmaceuticals to acquire Santarus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...